More recently, atezolizumab and cemiplimab both showed an OS and PFS benefit compared with chemotherapy in treatment-naïve advanced NSCLC with high PD-L1 expression [3,4]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.